Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study

NCT00485407 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00485407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
June 30, 2005
Enrollment
377 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder